Company news

Larimar Therapeutics, Inc. news in 2026

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

November 5, 2026

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

September 29, 2026

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

August 4, 2026

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

June 29, 2026

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

June 26, 2026

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

May 14, 2026

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

April 30, 2026

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

March 19, 2026

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

March 4, 2026

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

February 25, 2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

February 24, 2026

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

February 23, 2026

Decks in 2026